secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001641172-25-013249
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent
--------------------------------------------------------------------------------

- Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
- Approved amendment to increase authorized common stock from 100M to 150M shares.
- Approved reverse stock split at Board's discretion within 1-for-10 to 1-for-15 ratio.
- Approved stockholder action by written consent, removing meeting-only requirement.
- Ratified Grant Thornton as auditor for 2025 and approved potential issuance >20% under March 31 securities purchase agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/0001641172-25-013249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000164117225013249/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer